VEEV
Price
$322.69
Change
+$2.13 (+0.66%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
51.9B
28 days until earnings call
Intraday BUY SELL Signals
WAY
Price
$28.98
Change
+$0.14 (+0.49%)
Updated
Oct 22 closing price
Capitalization
5.56B
11 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

VEEV vs WAY

VEEV vs WAY Comparison Chart in %
View a ticker or compare two or three
VS
VEEV vs. WAY commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VEEV is a StrongBuy and WAY is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for VEEV with price predictions
Oct 22, 2026

Momentum Indicator for VEEV turns positive, indicating new upward trend

VEEV saw its Momentum Indicator move above the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 58 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for VEEV just turned positive on October 09, 2026. Looking at past instances where VEEV's MACD turned positive, the stock continued to rise in 31 of 52 cases over the following month. The odds of a continued upward trend are 60%.

Following a +1.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

The Aroon Indicator entered an Uptrend today. In 137 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

VEEV broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.984) is normal, around the industry mean (3.981). VEEV has a moderately high P/E Ratio (51.702) as compared to the industry average of (13.628). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.065).

The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock better than average.

A.I.Advisor
a Summary for WAY with price predictions
Oct 22, 2026

Momentum Indicator for WAY turns positive, indicating new upward trend

WAY saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator turned positive. In 38 of the 42 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for WAY just turned positive on October 06, 2026. Looking at past instances where WAY's MACD turned positive, the stock continued to rise in 19 of 23 cases over the following month. The odds of a continued upward trend are 83%.

Following a +0.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAY advanced for three days, in 110 of 139 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 69 of 79 cases where WAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The 10-day RSI Indicator for WAY moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In 11 of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

WAY broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. WAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.394) is normal, around the industry mean (3.981). P/E Ratio (40.817) is within average values for comparable stocks, (13.628). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (6.065).

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

FUNDAMENTALS RATINGS
VEEV: Fundamental Ratings
VEEV
OUTLOOK RATING
1..100
43
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
PROFIT vs RISK RATING
1..100
89
SMR RATING
1..100
58
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
58
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
VEEVWAY
RSI
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
68%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 21 days ago
65%
Bearish Trend 10 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
68%
Aroon
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
87%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (VEEV: $320.55 vs. WAY: $28.84)
Brand notoriety: VEEV and WAY are both not notable
Both companies represent the Services to the Health Industry industry
Current volume relative to the 65-day Moving Average: VEEV: 85% vs. WAY: 76%
Market capitalization -- VEEV: $51.9B vs. WAY: $5.56B
VEEV [@Services to the Health Industry] is valued at $51.9B. WAY’s [@Services to the Health Industry] market capitalization is $5.56B. The market cap for tickers in the [@Services to the Health Industry] industry ranges from $708 to $51.9B. The average market capitalization across the [@Services to the Health Industry] industry is $3.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VEEV’s FA Score shows that 0 FA rating(s) are green while WAY’s FA Score has 0 green FA rating(s).

  • VEEV’s FA Score: 0 green, 5 red.
  • WAY’s FA Score: 0 green, 5 red.
According to our system of comparison, VEEV is a better buy in the long-term than WAY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VEEV’s TA Score shows that 4 TA indicator(s) are bullish while WAY’s TA Score has 4 bullish TA indicator(s).

  • VEEV’s TA Score: 4 bullish, 4 bearish.
  • WAY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both VEEV and WAY are a good buy in the short-term.

Price Growth

VEEV (@Services to the Health Industry) experienced а +7.80% price change this week, while WAY (@Services to the Health Industry) price change was +7.33% for the same time period.

The average weekly price growth across all stocks in the @Services to the Health Industry industry was -1.51%. For the same industry, the average monthly price growth was -3.63%, and the average quarterly price growth was +16.27%.

Reported Earning Dates

VEEV is expected to report earnings on Nov 19, 2026.

WAY is expected to report earnings on Nov 02, 2026.

Industries' Descriptions

@Services to the Health Industry (-1.51% weekly)

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

View a ticker or compare two or three
VEEV
Daily Signal:
Gain/Loss:
WAY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

VEEV and

Correlation & Price change

A.I.dvisor indicates that over the last year, VEEV has been loosely correlated with CLSK. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VEEV jumps, then CLSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VEEV
1D Price
Change %
VEEV100%
+0.62%
CLSK - VEEV
55%
Loosely correlated
-6.86%
COIN - VEEV
54%
Loosely correlated
-4.51%
RIOT - VEEV
50%
Loosely correlated
-8.06%
WAY - VEEV
49%
Loosely correlated
+0.49%
PHR - VEEV
46%
Loosely correlated
+3.75%
More

WAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, WAY has been loosely correlated with VEEV. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if WAY jumps, then VEEV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WAY
1D Price
Change %
WAY100%
+0.49%
VEEV - WAY
50%
Loosely correlated
+0.62%
PHR - WAY
46%
Loosely correlated
+3.75%
TDOC - WAY
46%
Loosely correlated
+0.32%
HQY - WAY
44%
Loosely correlated
+3.16%
HSTM - WAY
39%
Loosely correlated
+3.22%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TARS72.081.58
+2.24%
Tarsus Pharmaceuticals
TROW103.450.16
+0.15%
T Rowe Price Group
CUE18.89-0.06
-0.32%
Cue Biopharma Inc.
CTKB5.43-0.07
-1.27%
Cytek Biosciences
FMST0.46-0.03
-5.17%
Foremost Clean Energy Ltd
Interesting Articles